M.S. BUTUSOVA¹, YU.D. UDALOV¹, YU.S. KITAEVA ², B.I. YURGIN¹, E.YU. SUMOROKOVA², E.A. PRASKURNICHY¹

 ¹Federal Medical Biophysics Center named after A.I. Burnazyan, Moscow

²N.I. Pirogov Russian National Research Medical University, Moscow

 Contact details:

Butusova M.S. — postgraduate student of the Therapy Department

Address: 46 Zhivopisnaya St., 123098 Moscow, Russian Federation, tel.: +7-908-928-13-99, e-mail: e.butusova@list.ru

 Osteoporosis in young people, whether primary or secondary, is a serious and pressing issue in clinical practice. Primary osteoporosis, which is relatively rare, is caused by genetic disorders, congenital anomalies, or disturbances in bone metabolism. A significantly more common secondary osteoporosis develops as a result of a long-term course of various chronic diseases or a complication of their treatment. Key factors triggering secondary osteoporosis include endocrine disorders; syndromes associated with delayed puberty; and prolonged treatment with glucocorticoid hormones and cytostatic drugs. Furthermore, the risk is increased by clinical conditions associated with prolonged immobilization, insufficient or inadequate nutrition, low body weight, and high levels of inflammatory cytokines. It is important that most patients with acute leukemia have nonspecific risk factors for decreased bone mineral density at the time of diagnosis. The presented clinical case highlights the critical importance of a comprehensive assessment of all associated risks when administering high-dose chemotherapy to such patients.

Key words: secondary osteoporosis, risk factors, bone mineral density, young age

REFERENCES

1. Polozhayeva I.V., Aliyakparov M.T. Relevance of the problem of osteoporosis in young age and its early modern diagnosis. Mezhdunarodnyy zhurnal prikladnykh i fundamental′nykh issledovaniy, 2018, no. 2, pp. 115–120 (in Russ.).
2. Osteoporoz. Klinicheskiye rekomendatsii Minzdrava RF, 2021 [Osteoporosis. Clinical guidelines of the Ministry of Health of the Russian Federation, 2021], available at: https://cr.minzdrav.gov.ru/schema/87
3. Perl′mutter O.A., Yarikov A.V., Lobanov I.A. et al. Osteoporosis: current state of the problem, modern methods of neuroimaging and principles of treatment. Vrach, 2020, no. 12, pp. 52–60 (in Russ.).
4. Klinicheskiye rekomendatsii «Ostryye limfoblastnyye leykozy» 2020, 2021, 2022 (20.01.2023). Utverzhdeny Minzdravom RF [Clinical guidelines «Acute lymphoblastic leukemia» 2020, 2021, 2022 (20.01.2023). Approved by the Ministry of Health of the Russian Federation].
5. Ulanova A.S., Grigor′yeva N.A., Turabov I.A. et al. Lesions of the bone and joint system at the onset of acute leukemia in childhood. Rossiyskiy vestnik perinatologii i pediatrii, 2020, no. 5, p. 65 (in Russ.).
6. Skvortsova Yu.V., Balashov D.N., Skorobogatova E.V. et al. Impaired bone mineralization after allogeneic hematopoietic stem cell transplantation in children: a single-center cohort study. Pediatricheskaya farmakologiya, 2017, no. 14 (6), pp. 459–468 (in Russ.).
7. Bagrova S.G., Basin E.M., Valiyev A.K. et al. Prevention and treatment of bone tissue pathology in malignant neoplasms. Malignant tumors: Practical recommendations. RUSSCO, 2022, vol. 12, pp. 40–54 (in Russ.).
8. Bo Liang, George Burley, Shu Lin etc. Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell. Mol. Biol. Letters, 2022, vol. 27, p. 72.
9. Gal′chenko A.V. The influence of lifestyle factors on bone metabolism and the risk of osteoporosis. Profilakticheskaya meditsina, 2022, vol. 25, no. 6, pp. 96–107 (in Russ.).
10. Kitayeva Yu.S., Praskurnichiy E.A. Predictors of decreased bone mineral density in patients with Hodgkin’s lymphoma associated with pathogenetic therapy. Arkhiv vnutrenney meditsiny, 2023, vol. 13, no. 1, pp. 36–45 (in Russ.).
11. Praskurnichiy E.A. Risk factors for osteoporosis and osteopenia associated with pathogenetic therapy of Hodgkin’s lymphoma. Kremlevskaya meditsina. Klinicheskiy vestnik, 2022, no. 4, pp. 5–8 (in Russ.).
12. Risk factors for osteoporosis and fractures. Osteoporoz i osteopatii, 2009, vol. 12, no. 1, pp. 33–38 (in Russ.). DOI:10.14341/osteo2009133-38
13. Grebennikova T.A., Troshina V.V., Belaya Zh.E. Markers and genetic predictors of osteoporosis in routine clinical practice. Consilium Medicum, 2019, vol. 21, no. 4, pp. 97–102 (in Russ.).
14. Masheyko I.V. Biochemical markers in the assessment of bone remodeling processes in osteopenia and osteoporosis. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta, 2017, no. 2, pp. 49–53 (in Russ.).
15. Drygina L.B., Trofimova I.V., Sablin O.A. et al. Sovremennyye metody diagnostiki, profilaktiki i lecheniya osteoporoza. Metodicheskoye posobiye [Modern methods of diagnosis, prevention, and treatment of osteoporosis. Methodological manual]. Saint Petersburg: VTSERM im. A.M. Nikiforova MCHS Rossii, 2011. P. 86.
16. Management of osteoporosis: a national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN), 2003, vol. 71.
17. Institute for Clinical Systems Improvement (ICS!) Health Care Guideline: Diagnosis and Treatment of Osteoporosis, 3rd edition, July 2004, available at: www.icsi.org (accessed on: 11.10.2004).
18. Ostroumova O.D., Goloborodova I.V. Medicines, the use of which is associated with the development of osteoporosis. Farmateka, 2020, no. 4 (in Russ.). DOI: 10.18565/pharmateca.2020.4.108-118
19. Krasivina I.G., Dolgova L.N., Dolgov N.V. et al. Pathogenesis and prevention of glucocorticoid-induced osteoporosis. Meditsinskiy sovet, 2019, no. 21, pp. 121–129 (in Russ.).
20. Ostroumova O.D., Goloborodova I.V. Drugs associated with the development of osteoporosis. Farmateka, 2020, no. 4, pp. 108–118 (in Russ.).
21. Ostroumova O.D., Goloborodova I.V. Drug-induced osteoporosis. Klinicheskaya farmakologiya i terapiya, 2020, vol. 29, no. 3, pp. 73–79 (in Russ.).
22. Shaforostova I.I., Remizov A.N., Tereshchenko G.V. et al. Multifocal bone lesions in a patient with acute lymphoblastic leukemia. Voprosy gematologii / onkologii i immunopatologii v pediatrii, 2015, vol. 14, no. 1, pp. 62–63 (in Russ.).
23. Savchenko V.G., Parovichnikova E.N. Ostryye leykozy. Klinicheskaya onkogematologiya: rukovodstvo dlya vrachey. 2-e izd., pererabotannoye i dopolnennoye [Acute leukemia. Clinical oncohematology: a manual for physicians. 2nd ed., revised and supplemented]. Moscow: LitTerra, 2007.
24. Parovichnikova E.N., Troitskaya V.V., Klyasova G.A. et al. Treatment of patients with acute myeloid leukemia according to the protocol of the Russian multicenter randomized study AML-01.10: results of the coordination center. Terapevticheskiy arkhiv, 2014, no. 7, pp. 14–23.
25. Skvortsova Yu.V., Balashov D.N., Maschan A.A. Osteopenia and osteoporosis after allogeneic hematopoietic stem cell transplantation, features of bone mineral metabolism disorders in children. Voprosy gematologii / onkologii i immunopatologii v pediatrii, 2017, vol.16, no. 4, pp. 98‒106 (in Russ.).
26. Carpenter P.A., Kitko C.L., Elad S. et al. National Institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant, 2015, p. 87.
27. Murasheva K.D. Complications of chemotherapy. Cardiotoxicity of anthracycline antibiotics. FORCIPE, 2021, no. S1, pp. 625–626.
28. Bal′zhanova Ya.B., Sorkina O.M., Grachev A E. et al. Bone damage in B-cell acute lymphoblastic leukemia. Gematologiya i transfuziologiya, 2022, no. S2, p. 159 (in Russ.).
29. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int, 2002, p. 87.
30. Rizzo J.D., Wingard J.R., Tichelli A. et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol. Blood Marrow Transplant, 2006, p. 51.
31. Badykova K.M., Kitayeva Yu.S., Praskurnichiy E.A. et al. Staged treatment of femoral neck fractures associated with osteoporosis and hemoblastosis: description of a clinical case. Klinicheskiy vestnik FMBTS im. A.I. Burnazyana, 2025, no. 1, pp. 42–48 (in Russ.).
32. Kitayeva Yu.S., Badykova K.M., Praskurnichiy E.A. Diagnostic Features of Acute Lymphoblastic Leukemia with Debuts in the Bone System. A Case Report. Sibirskoye meditsinskoye obozreniye, 2024, vol. 147, no. 3, pp. 97–101 (in Russ.).
33. Bagrova S.G., Basin E.M., Valiyev A.K. et al. Prevention and Treatment of Bone Pathology in Malignant Neoplasms. Malignant Tumors: Practical Recommendations. RUSSCO, 2022, vol. 12, no. 3S, pp. 40–54.